Side Effects Trajectories in rTMS Treatment for Depression: High Frequency Left (10 Hz) vs. Intermittent Theta-Burst Stimulation

Afifa Humaira1, Sihaoyu Gao1, Lang Wu1, Jonathan Downar2, Daniel Blumberger3, Fidel Vila-Rodriguez1

1Non-Invasive Neurostimulation Therapies (NINET) Laboratory, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada, 2University of Toronto, Canada, 3Department of Psychiatry, Centre for Addiction and Mental Health, University of Toronto, 250 College Street, Floor 8, Toronto, ON M5T 1R8, Canada

Introduction

According to WHO, Major Depressive Disorder (MDD) is a leading cause of disability that affects 350 million people worldwide, and 30% of them suffer from treatment-resistant depression (TRD). Repetitive Transcranial Magnetic Stimulation (rTMS) is a first-line treatment for TRD. Newer rTMS protocols are being developed and it is extremely important to characterize their side effect profile and trajectories. Therefore, the goal of this work is to compare the side effects of two rTMS protocols, namely High Frequency Left (10 Hz) and Intermittent Theta Burst Stimulation (iTBS), in 20 patients with TRD from a study conducted by the Non-Invasive Neurostimulation Therapies Lab at the University of British Columbia, Department of Psychiatry.

High Frequency Left 10 Hz (HFL)
- Conventional
- 37 minutes/session

Intermittent Theta Burst Stimulation (iTBS)
- Newer protocol
- 3 minutes/session

Methods and Materials

The main goal of this project is to explore the common side effects of rTMS that emerged in 20 patients in the study, and to compare the frequency and severity trends of the reported side effects for both HFL and iTBS protocols throughout the course of the treatment, by analyzing different side effects questionnaires completed by the participants.

How to quantify/measure side effects in this study:
- Treatment Confirmation: Completed by RA throughout tr: side effects are asked by RA and answered by pt
- Comfort Rating Questionnaire (CRQ): A: Self-reported by patient on a lab tablet/computer a few minutes after tx

20 Patients Diagnosed with TRD

HFL (10 pt) vs. iTBS (10 pt)

Treatment
- 5 sessions/week (1 tx session/day)
- 4–6 weeks of treatment
- 20–30 tx sessions in total

Results

- # of Pt Reporting Side Effect Since Last Tx or Current Tx at Least Once
- 10 Hz vs. iTBS: # of Pt Reporting Side Effects Since Last Tx / During Current Tx at Least Once

Methodology

Conclusions

1. Pain on stimulation site, headache, and fatigue are the three most common side effects of rTMS, with pain/discomfort being the most frequent one, where all patients reported to have experienced it at least once over the course of the treatment.
2. The side effect scores for pain, headache, and fatigue show a significant decrease over time (p-values of 0.0000, 0.0294, and 0.0012 respectively).
3. Patients who received HFL (10 Hz) protocol report higher severity of fatigue (p-value of 0.0275) than patients who received iTBS protocol, when the treatment time is controlled.
4. Patients who received HFL (10 Hz) protocol report higher severity of headache (p-value of 0.0263) than patients who received iTBS protocol, when the treatment time is controlled.
5. Additionally, female subjects report higher severity of headache than male subjects (p-value of 0.0577), when the treatment time is controlled.
6. Female subjects report higher severity of headache than male subjects (p-value of 0.0577), when the treatment time is controlled.
7. Lastly, stimulation intensity, age, and responsiveness (i.e., responders vs. non-responders) do not have significant effect side effect scores on pain, headache, and fatigue.

Discussion

1. A main drawback of this dataset is that the sample size of 20 is small, so a larger sample size is needed to confirm the above conclusions.
2. The fact that the HFL group patients are exposed to the rTMS stimulation 10 times longer per session than the iTBS group could explain why they experience more severe side effect like headache and fatigue post-treatment.
3. With a larger sample size, other covariates like stimulation intensity, age, and responsiveness of the patients could be further assessed to see if there are significant differences of the side effect scores between the groups.
4. The results of this project could be important for future patients and clinicians in deciding which rTMS protocol to receive/administer, so that the patients could be informed of this knowledge to help make a decision on which treatment would be most tolerable.